Half-year Financial Report

AI SummaryClose X

OptiBiotix Health plc reported a revenue increase of 21.9% to £679,000 for the six months ended 30 June 2026, with gross profit rising 25.4% to £380,000 and the gross profit margin improving to 55.9%. Operating costs decreased by 12.2% to £1.01 million, driven by a 69.5% reduction in selling costs to £76,000. Sales in the Rest of the World, primarily Asia, surged by 133%, now accounting for 49% of Group sales. The company ended the period with net assets of £4.73 million and a cash position of £0.99 million, while also announcing post-period agreements for US and Indian market launches and progress on its SweetBiotix product.

Disclaimer*

UK 100

Latest directors dealings